Fineline Cube

Follow:
14435 Articles
Medtronic Q3 Earnings Show 4.1% Organic Growth, Driven by Cardiac Ablation
Company

Medtronic Q3 Earnings Show 4.1% Organic Growth, Driven by Cardiac Ablation

QuantumPharm and Hengjian Launch GBA AI+ Innovation Consortium
CompanyDeals

QuantumPharm and Hengjian Launch GBA AI+ Innovation Consortium

Deepwise Information Integrates DeepSeek into Medical Data Platform
Company

Deepwise Information Integrates DeepSeek into Medical Data Platform

Weimai Qingtong Medical Technology Completes Tens of Millions Yuan B+ Round
Company

Weimai Qingtong Medical Technology Completes Tens of Millions Yuan B+ Round

InnoCare Pharma Receives NMPA Approval for Mesutoclax Phase III Study in CLL/SLL
CompanyDrug

InnoCare Pharma Receives NMPA Approval for Mesutoclax Phase III Study in CLL/SLL

Hengrui Pharma's HR19034 Eye Drops for Myopia Delay Accepted by NMPA
CompanyDrug

Hengrui Pharma’s HR19034 Eye Drops for Myopia Delay Accepted by NMPA

Gan & Lee Pharmaceuticals Doses First Patient in GZR4 Phase III Study for Diabetes
CompanyDrug

Gan & Lee Pharmaceuticals Doses First Patient in GZR4 Phase III Study for Diabetes

Stedical Scientific Raises RMB100M in Series B Financing for Global Expansion
CompanyDeals

Stedical Scientific Raises RMB100M in Series B Financing for Global Expansion

Zelgen Biopharmaceuticals' ZG005 Bispecific Antibody Receives NMPA Approval for Biliary Tract Cancer Trials
CompanyDrug

Zelgen Biopharmaceuticals’ ZG005 Bispecific Antibody Receives NMPA Approval for Biliary Tract Cancer Trials

Bristol-Myers Squibb Releases Five-Year Data on Sotyktu's Long-Term Efficacy and Safety
CompanyDrug

Bristol-Myers Squibb Releases Five-Year Data on Sotyktu’s Long-Term Efficacy and Safety

Wanbangde New Building Materials' Mecobalamin Earns FDA Orphan Drug Designation for ALS
CompanyDrug

Wanbangde New Building Materials’ Mecobalamin Earns FDA Orphan Drug Designation for ALS

Biokin Pharmaceutical Registers Phase III Study for BL-B01D1 in EGFR Mutant NSCLC
CompanyDrug

Biokin Pharmaceutical Registers Phase III Study for BL-B01D1 in EGFR Mutant NSCLC